ClinicalTrials.gg
RecruitingNCT07196332RESTUpdated Oct 29, 2026

Recovering Sleep After Trauma

An interventional study of Brief Behavioral Treatment for Insomnia (BBTI) and Progressive Muscle Relaxation Training (PMRT) in Post-traumatic Stress Disorder, sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 29, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Stress Disorders, Post-Traumatic by University of North Carolina, Chapel Hill — 4 open to participants now, 4 under way, none of them phase 3. Stress Disorders, Post-Traumatic · University of North Carolina, Chapel Hill.

Planned enrollment
10th of 10
20 · median 43
Started
2026
with 2 others
No phase
7 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Stress Disorders, Post-Traumatic by University of North Carolina, Chapel Hill, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 with no phase, and was the 10th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

4 of the 11 studies in Stress Disorders, Post-Traumatic by University of North Carolina, Chapel Hill are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stress Disorders, Post-Traumatic by University of North Carolina, Chapel Hill, or all of them as a file.
02

Study summary

The main objective of this pilot trial is to assess the feasibility and preliminary efficacy of telehealth-delivered behavioral therapy to reduce the development of posttraumatic stress and depressive symptoms following motor vehicle collision among individuals at high risk. This pilot trial will provide the data necessary to design and support a large-scale trial.

Read the detailed description

Each year, more than 40 million Americans present to US emergency departments (EDs) for evaluation after traumatic stress exposure. The overwhelming majority of these individuals are discharged home after evaluation. A wealth of data demonstrates that the development of adverse posttraumatic neuropsychiatric sequelae such as posttraumatic stress disorder (PTSD) is common in this population, and that individuals with a history of traumatic stress exposure and/or posttraumatic stress symptoms-such as military veterans-are at increased risk. Unfortunately, no secondary preventive interventions are currently widely available that can prevent PTSD among those at high risk. This pilot REST trial will assess the ability of brief behavioral treatment for insomnia (BBTI) to reduce the incidence and severity of PTSD and depression after one of the most common traumatic stress exposures in industrialized countries, motor vehicle collision (MVC). BBTI is an evidence-based, low-cost intervention that has been demonstrated to be effective in treating insomnia and reducing PTSD symptoms. However, BBTI has never been tested as a secondary preventive intervention for PTSD and depression. In addition, the efficacy of BBTI when administered as a telehealth intervention has never been assessed. This REST pilot trial will randomize 20 (N=20) individuals who present to a study ED for care after MVC to four sessions of brief behavioral treatment for insomnia (BBTI) versus a progressive muscle relaxation training (PMRT) control. Both interventions will be administered via telehealth, with 10 individuals receiving BBTI and 10 receiving PMRT. Each therapist will administer both interventions. Participants will be assessed via traditional self-report surveys and sleep diaries. Results of this trial will demonstrate the feasibility and potential efficacy of BBTI to prevent the development of PTSD and depression after traumatic stress exposure and will provide the data necessary to design/support a large-scale trial. Developing preventive interventions to reduce PTSD and depression among individuals experiencing civilian trauma exposures would reduce suffering and considerable costs associated with these disorders.

03

Conditions studied

  • Post-traumatic Stress Disorder

Keywords

  • Trauma and Stressor Related Disorders
  • Mental Disorders
  • Stress Disorders, Traumatic
  • Stress Disorders, Post-Traumatic
  • Motor Vehicle Collision
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Alert and oriented at time of screening
  2. Written and spoken English
  3. Age 18-65
  4. Presents to the ED within 72 hours of MVC
  5. Discharged home after ED evaluation
  6. Has an email and mailing address
  7. Owns a smartphone compatible with iOS or Android, has not experienced service interruption due to non-payment in the past year, and has maintained the same phone number for at least one year
  8. Meets PTSD risk score criteria (score of ≥ 16 on the PTSD risk stratification tool)
  9. Willing to participate in four remote therapy sessions

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 or >65
  2. Pregnant
  3. Prisoner or in police custody
  4. Present to ED >72 hours after trauma
  5. Admitted to the hospital after ED evaluation
  6. Severely injured (e.g., severely broken bones) as a result of the MVC that, in the opinion of the investigator, may impact PTSD trajectories
  7. Had a change in psychiatric medication or psychotherapy regimen within 1 month of enrollment
  8. Currently receiving or planning to receive evidence-based treatments that directly target insomnia or PTSD (e.g., CBT-I, Cognitive Processing Therapy, or Prolonged Exposure Therapy)
  9. MVC was self-inflicted or occupation-related
  10. Report or indicate that they are experiencing ongoing domestic violence
  11. Has conditions that may be associated with comorbid insomnia, including a lifetime history of any psychiatric disorder with psychotic features, manic or hypomanic episodes. We will not exclude individuals based on any other mental health condition, including depression
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Brief Behavioral Treatment for Insomnia (BBTI)

    Four sessions of telehealth-delivered brief behavioral treatment for insomnia

    Behavioral: Brief Behavioral Treatment for Insomnia (BBTI)

  • Active comparator
    Progressive Muscle Relaxation Training (PMRT)

    Four sessions of telehealth-delivered progressive muscle relaxation training

    Behavioral: Progressive Muscle Relaxation Training (PMRT)

Interventions

  • BehavioralBrief Behavioral Treatment for Insomnia (BBTI)

    In the first week, treatment consists of a 60-minute video individual intervention session; in the second week, participants receive a 30-minute phone call; in the third week, treatment consists of a 45-minute video individual session; the final session consists of a 30-minute phone call. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of homeostatic and circadian mechanisms of human sleep regulation. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.

  • BehavioralProgressive Muscle Relaxation Training (PMRT)

    In the first week, treatment consists of a 60-minute video individual intervention session; in the second week, participants receive a 30-minute phone call; in the third week, treatment consists of a 45-minute video individual session; the final session consists of a 30-minute phone call. Treatment begins with learning how to alternately tense and relax 14 major muscle groups, and then to use progressively more efficient tensing-relaxing and passive relaxation exercises, with sessions used to teach techniques and problem-solve barriers to its daily use.

06

What researchers measure

Primary outcomes

  1. Changes in PTSD Symptom Severity Over Time

    The PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report measure designed to assess PTSD symptoms as defined by the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5). The PCL-5 will be completed in reference to the motor vehicle collision (MVC) that occurred just before enrollment into the study. Each item of the PCL-5 is scored on a five-point scale ranging from 0 ("not at all") to 4 ("extremely"). Items are summed to provide a total severity score (range = 0-80), with higher scores indicating greater symptom severity. PTSD symptom severity will be compared between treatment groups over time.

    Time frame: Baseline, Week 4, Week 8, Month 3

  2. Recruitment Rates

    To assess the feasibility of the study recruitment protocol, the proportion of eligible participants who enroll in the study and are randomized will be calculated.

    Time frame: Baseline

  3. Retention Rates

    To assess feasibility of the study protocol, the proportion of participants who complete the study protocol, according to study arm and in total, will be calculated.

    Time frame: Month 3

  4. Treatment Completion Rates

    To assess feasibility of the treatment protocol, treatment completion rates will be calculated according to the study arm and in total. Treatment completers will be defined as participants who complete at least 3 out of 4 REST or control sessions.

    Time frame: Week 4

Secondary outcomes

  1. Change in Depressive Symptom Score Over Time

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short Form 8b is an 8-item scale developed to assess depression in individuals 18 and older. Each item is rated on a five-point scale. For this study, response options are slightly altered for greater consistency across measures and precision in response levels (i.e., 1 = "never" is changed to none of the time and 5 = "always" is changed to "all or almost all of the time."). Items are summed to provide a total severity score (range = 8-40), with higher scores indicating greater severity of depression. Depressive symptom severity will be compared between treatment groups over time.

    Time frame: Baseline, Week 4, Week 8, Month 3

  2. Change in Somatic Score Symptoms Over Time

    Somatic symptoms will be assessed using a modified version of the Pennebaker Inventory of Limbic Languidness (PILL), which assesses the frequency of common physical symptoms and sensations. Each item is scored on a 0-10 scale where 0 indicates no problems. Number of moderate to severe somatic symptoms (scores ≥ 4) will be compared between groups.

    Time frame: Baseline, Week 4, Week 8, Month 3

  3. Change in Pain Symptom Severity and Extent Over Time

    Pain severity and extent will be evaluated using a modified version of the Regional Pain Scale, where each item is scored on a 0-10 numeric rating with 0 indicating no pain and 10 indicating severe pain. Pain symptom severity and extent will be compared between treatment groups over time.

    Time frame: Baseline, Week 4, Week 8, Month 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual data that supports the results will be shared on request provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina (UNC).

Time frame: Beginning 12 months following publication and continuing for 36 months.

Access criteria: Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 17 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2025
First posted
Sep 29, 2025
StartActual
Apr 30, 2026
Primary completionEst.
Sep 2027was Sep 2026
CompletionEst.
Sep 2027was Sep 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Sep 2027
Oct 29, 2026
Study completion
Sep 2026→Sep 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Sep 2026→Sep 2027
    Study completion Sep 2026→Sep 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07196332
Collaborators
Heart and Armor Foundation
Responsible party
Sponsor
First posted
Sep 29, 2025
Start date
Apr 30, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Andrea A Massa, PhD
Contact
REST@unc.edu
(919) 966-1644
Romina Soudavari, MPH
Contact
REST@unc.edu
(919) 966-1644
Samuel McLean, MD, MPH
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion